Q1 2024 · 13F-HR
Casdin Capital, LLCholdings as filed
Filed 2024-05-15 · accession 0000919574-24-003198
$1.35B
Reported value
37
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $181.1M | 13.5% | 5,617,599 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $167.8M | 12.5% | 61,907,605 | Common | SOLE |
| 09062W204 | BLFS | BIOLIFE SOLUTIONS INC | $161.5M | 12.0% | 8,707,165 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $138.4M | 10.3% | 1,069,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $61.6M | 4.58% | 7,423,574 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $53.5M | 3.98% | 358,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $53.2M | 3.96% | 2,084,841 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $51.6M | 3.83% | 1,875,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $47.9M | 3.56% | 1,116,867 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $44.9M | 3.34% | 650,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $40.6M | 3.02% | 3,059,094 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $35.2M | 2.62% | 6,732,971 | Common | SOLE |
| 452327109 | ILMN | ILLUMINA INC | $34.1M | 2.53% | 248,000 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $31.0M | 2.30% | 326,378 | Common | SOLE |
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $28.6M | 2.13% | 3,136,411 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $26.7M | 1.99% | 524,616 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $26.7M | 1.98% | 1,300,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $25.5M | 1.89% | 800,000 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $22.3M | 1.66% | 675,000 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $19.0M | 1.41% | 857,904 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $14.9M | 1.11% | 1,000,000 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $13.4M | 1.00% | 3,206,380 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $10.7M | 0.80% | 2,000,000 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $10.7M | 0.79% | 2,360,129 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $9.4M | 0.70% | 1,188,349 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $7.0M | 0.52% | 2,000,000 | Common | SOLE |
| 00091E109 | ABSI | ABSCI CORPORATION | $5.5M | 0.41% | 973,260 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $3.9M | 0.29% | 1,035,859 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $3.7M | 0.28% | 150,000 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $3.6M | 0.27% | 510,882 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $3.6M | 0.27% | 150,000 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $2.6M | 0.19% | 367,175 | Common | SOLE |
| 37611X100 | DNA4EUR | GINKGO BIOWORKS HOLDINGS INC | $1.7M | 0.13% | 1,459,747 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $1.4M | 0.10% | 50,000 | CALL | SOLE |
| 30223G102 | EXAIEUR | EXSCIENTIA PLC | $1.2M | 0.09% | 213,900 | Common | SOLE |
| 82933R100 | — | SINGULAR GENOMICS SYSTEMS IN | $680,742 | 0.05% | 1,323,885 | Common | SOLE |
| 50107A104 | KRON1USD | KRONOS BIO INC | $160,991 | 0.01% | 123,839 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.